唑来膦酸联合化疗治疗非小细胞肺癌骨转移的临床效果

Abstract
Figure/Table
References (20)
Related Citation (15)

Download: PDF (0 KB) HTML (32 KB)
Export: BibTeX | EndNote (RIS)

Abstract Objective To analyze the clinical effect of Zoledronic Acid combined with chemotherapy treating bone metastasis of non-small cell lung cancer(NSCLC),in order to provide reference for the selection of clinical treatment.Methods The clinical data of 82 patients with NSCLC bonemetastasiswho were treated in our hospital from January 1,2018 to January 1,2019 were analyzed retrospectively.According to the different treatmentmethods,they were divided into two groups.A total of 39 patients who received conventional chemotherapy were set as the control group and 43 patientswho received chemotherapy and Zoledronic Acid as the observation group.The clinical effect,bone pain score and adverse reactions were observed.Results The disease control rate of the observation group(93.02%)was higher than that of the control group(76.92%),the differencewas statistically significant(P＜0.05).Before treatment,there was no significant difference between the two groups in numeric rating scale(NRS)score(P＞0.05).After treatment,the NRS scores of both groups were lower than those before treatment,the NRSscore of the observation group([1.42±0.91]points)was lower than that of the control group([2.59±1.27]points),the differences were statistically significant(P＜0.05).The incidence rates of gastrointestinal reactions,bonemarrow suppression and fever in the observation group and the control group were compared(23.26%vs.30.77%,20.93%vs.17.95%,11.63%vs.7.69%),with no significant difference(P＞0.05).Conclusion Zoledronic Acid combined with chemotherapy treating NSCLC bonemetastasis can improve the symptoms of bone pain,inhibit the growth and progress of tumor,and improve the therapeutic effect without increasing adverse reactions.

Key words： Non-small cell lung cancer Bonemetastasis Zoledronic Acid Chemotherapy Bone pain symptoms Adverse reactions

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	LIU Shuang
	QI Ying
	LIU Yong

Cite this article:

LIU Shuang,QI Ying,LIU Yong. Clinical effect of Zoledronic Acid combined with chemotherapy treating bonemetastasis of non-small cell lung cancer[J]. 中国当代医药, 2020, 27(9): 85-87.

URL:

http://dangdaiyiyao.com/EN/ OR http://dangdaiyiyao.com/EN/Y2020/V27/I9/85

[1]	王永芳，张春芳，陈昊.干细胞转录因子SOX2与非小细胞肺癌的研究进展[J].实用医学杂志，2018，34（16）：2807-2810.
[2]	朱丽华，陈尚雅，李和根，等.晚期非小细胞肺癌中医药联合外治法的临床研究[J].世界中医药，2017，12（1）：34-36，41.
[3]	蒋晓岚，王佳.非小细胞肺癌骨转移患者预后影响因素分析[J].山东医药，2016，56（35）：88-90.
[4]	朱勇，鲁正学，朱媛，等.放疗联合吉西他滨及顺铂放化疗对Ⅲ期非小细胞肺癌患者的疗效及QOL评分的影响[J].实用癌症杂志，2018，33（10）：1662-1664，1668.
[5]	刘丽，李涛，郎锦义，等.同步放化疗联合恩度治疗ⅢB和Ⅳ期非小细胞肺癌临床研究[J].肿瘤预防与治疗，2017，30（4）：265-270.
[6]	何玉峰，陈进，鲁光平，等.来曲唑联合唑来膦酸治疗ER/PR阳性的绝经后乳腺癌骨转移疗效分析[J].山东医药，2016，56（35）：65-67.
[7]	化改改，朱琰琰，王朝杰，等.负荷剂量伊班膦酸钠与常规剂量唑来膦酸联合化疗胃癌骨转移的疗效观察[J].实用癌症杂志，2019，34（3）：424-427.
[8]	李林法.现代骨转移瘤诊治学[M].北京：科学出版社，2006：256-258.
[9]	陈彬，张玲，徐海燕.影响非小细胞肺癌骨转移患者预后的非条件Logistic回归分析[J].实用癌症杂志，2018，33（1）：79-81.
[10]	李军，陈芳，卢萍，等.晚期非小细胞肺癌患者采用吉西他滨联合顺铂方案化学疗法过程中监测外周血同型半胱氨酸水平的临床意义[J].华西医学，2016，31（8）：1380-1383.
[11]	易福梅，顾阳春，陈森，等.治疗前后NLR和PLR对进展期非小细胞肺癌一线化疗疗效及预后的预测价值[J].中国肺癌杂志，2018，21（6）：481-492.
[12]	曾少容，凌钦杰，曾维亮.唑来膦酸联合放射治疗对非小细胞肺癌骨转移患者癌痛的疗效观察[J].临床肿瘤学杂志，2017，22（2）：152-156.
[13]	王伟.唑来膦酸对晚期非小细胞肺癌骨转移患者的疗效及VEGF-C和COX2水平的影响[J].医学临床研究，2019，36（4）：640-642.
[14]	年峰，袁圆，王莉，等.羟考酮缓释片联合唑来膦酸治疗骨转移癌痛的效果观察[J].蚌埠医学院学报，2019，44（4）：470-472.
[15]	邱慧兵，易铁男，张凌云，等.唑来膦酸联合放疗与联合化疗治疗非小细胞肺癌骨转移效果观察[J].肿瘤研究与临床，2017，29（7）：437-441.
[16]	赵军，刘水中，王正志，等.唑来膦酸联合TP方案化疗治疗晚期非小细胞肺癌骨转移的效果及不良反应分析[J].肿瘤药学，2018，8（3）：374-377.
[17]	李宁，杨志，柴华，等.唑来膦酸联合89Sr治疗无症状非小细胞肺癌骨转移临床研究[J].中华肿瘤防治杂志，2018，25（13）：962-967.
[18]	梁研，郭进华.唑来膦酸联合化疗治疗非小细胞肺癌骨转移效果观察[J].肿瘤研究与临床，2016，28（5）：345-347.
[19]	张明慧，王跃蓉，付小明，等.奥施康定联合唑来膦酸治疗骨转移性癌痛的临床研究[J].现代肿瘤医学，2018，26（18）：2953-2955.
[20]	庄国柱.骨瘤康颗粒联合唑来膦酸治疗肾虚痰凝型骨转移癌痛疗效及对尿NTx水平的影响[J].现代中西医结合杂志，2018，27（6）：635-637.